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Does Underlying Plaque Morphology Play a Role in
Vessel Healing After Drug-Eluting Stent Implantation?*
Aloke V. Finn, MD,† Gaku Nakazawa, MD,‡ Elena Ladich, MD,‡ Frank D. Kolodgie, PHD,‡
Renu Virmani, MD, FACC‡
Atlanta, Georgia; and Gaithersburg, MarylandLack of complete endothelialization after the
implantation of a drug-eluting stent (DES) is the
major pathologic substrate underlying all cases of
late stent thrombosis (1). Although some of the
factors that help to determine the healing re-
sponse of these devices are thought to be stent
related (e.g., drug and polymer), others important
factors that are extrinsic to stent undoubtedly
exist. One of these is the underlying coronary
lesion morphology on which the stent is being
placed. Recent clinical outcomes and pathologic
data from patients dying after stent placement
suggest that patients receiving DES for indica-
tions other than stable angina have poorer clinical
outcomes and significantly delayed arterial heal-
ing of the stented segment (2,3). In this issue of
iJACC (JACC: Cardiovascular Imaging), Kubo et
See page 475
al. (4) extend these observations by demonstrating
that, with the use of optical coherences tomography
(OCT), a clear link exists between more complex
lesion morphologies (e.g., plaque rupture or thin
cap fibroatheroma [TCFA]) and the percent of
uncovered stent struts 9 months after the placement
of s sirolimus-eluting stent (SES). The markedly
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Prescient Medical, Biotronik, Jerini AG; Vascular Biogenics Ltd., Car-
dioMind, Atrium, Volcano Therapeutics, and nMemoscience GmbH.different responses of the vessel wall to DES im-
plantation in patients with stable angina versus
those with acute coronary syndromes implicates
lesion morphology as another important factor in
delayed healing after DES placement. These data
also support the contention that patients receiving
DES for indications other than stable angina may
be at increased risk for late stent thrombosis as the
result of excessively delayed healing at culprit sites.
We know from pathologic studies that there are
important differences in plaque morphology in pa-
tients presenting with stable versus unstable angina.
Plaque rupture is the predominant lesion underly-
ing all cases of acute coronary syndromes (Fig. 1)
(5). Plaque rupture is characterized by a necrotic
core with an overlying thin-ruptured cap infiltrated
by macrophages. Smooth muscle cells within the
cap are absent or few (Fig. 1). The thickness of the
fibrous cap near the rupture site measures 23  19
m, with 95% of caps measuring 65 m. It has
been observed that other plaques at nearby sites or
remote locations in the coronary tree resemble
ruptured plaques but lack a luminal thrombus and
have an intact cap. These plaques have been termed
TCFA or vulnerable plaques (Fig. 1). These 2 types
of lesions differ greatly from the stable plaques or
fibroatheromas/fibrocalcific lesions found in pa-
tients with stable angina (Fig. 1). The major differ-
ences are that fibroatheromas have a thicker fibrous
cap (i.e., 100 m), smaller necrotic core, fewer
inflammatory cells, greater percentage of collagen-
rich matrix, and are usually calcified. These same
characteristic differences were observed by Kubo et
al. (4) in the 2 groups of patients studied. There was
a significantly greater incidence of plaque rupture,
thrombus, lipid-rich plaque, and TCFA in the
unstable angina group. Moreover, fibrous cap thick-
ness was significantly less. These findings lend
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486redence to the use of OCT to distinguish plaque
orphologies.
The structure of plaques may affect the rela-
ionship of stent struts to underlying tissue and
herefore affect arterial responses to stent place-
ent including healing. In their assessment of
he relationship between lesion morphology be-
ore percutaneous coronary intervention and re-
ponses to stenting after percutaneous coronary
ntervention, lesions with plaque rupture, throm-
us, lipid-rich plaques, and TCFA demonstrated
greater incidence of inadequate stent apposi-
ion, tissue protrusion, and intracoronary throm-
us compared with those without these features.
lthough in both groups the incidence of malap-
osition decreased over time, in the unstable
roup, its incidence was still significantly greater
ompared with the stable group (33% vs. 4%, p 
.012).
Strut penetration of the necrotic core with result-
nt malapposition has important implications for
ealing. Lipid-rich necrotic cores are more avascu-
ar compared with fibrous plaques and have fewer
ells. Therefore, these lesions are less likely to be
overed by migrating and proliferating cells from
djacent areas (Fig. 2). Thin fibrous caps are either
evoid of or are thinly populated with smooth
uscle cells and, therefore, areas of injury and stent
Figure 1. Representative Histologic Sections From Various Type
In the left panels, stable lesions have a predominance of ﬁbrous tis
romas have a necrotic core (NC) with overlying thin ﬁbrous cap (FC
cap (FC) is disrupted (arrow) with superimposed thrombus (Thr).truts may not be able to be covered. Recently, 3ook et al. (6) compared the prevalence of incom-
lete stent apposition in a series of patients with
nd without late stent thrombosis after DES place-
ent and found it to be significantly more frequent
n the cases of late stent thrombosis (77% vs.12%, p
0.001). In our own series of human pathologic
pecimens, late malapposition is associated with the
resence of thrombus between stent struts and
nderlying plaque. We have also found a signifi-
antly greater prevalence of incomplete strut appo-
ition to the vessel wall in cases with versus those
ithout thrombus (29% vs. 6%, p  0.02) (7).
In addition to its role in facilitating incomplete
pposition, plaque morphology may also affect the
ate of healing of the stented segment after DES
lacement. We have demonstrated in human
athologic specimens that stent strut coverage cor-
elates highly with endothelialization, suggesting
hat neointimal coverage of stent struts could be
sed as a surrogate for endothelialization (1). Kubo
t al. (4) make use of these data by comparing
eointimal coverage of stent struts in patients with
table versus unstable angina. At 9 months, the
ncidence of SES demonstrating lack of full stent
trut coverage by neointima was significantly greater
n patients with unstable versus stable angina (28%
s. 63%, p  0.02) and the incidence of partially
ncovered struts was significantly greater (72% vs.
Plaque
(f) with calcium (Ca2). In the center panels, thin cap ﬁbroathe-
ow), whereas in the right panels, ruptured plaques, the ﬁbrouss of
sue
; arr7%, p 0.02). The volume and area of neointimal
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487yperplasia were also significantly less in the unsta-
le versus stable group.
These data are concordant with our own patho-
ogic studies in that we also find a greater percent-
ge of uncovered struts at the culprit site in patients
eceiving DES (i.e., SES and paclitaxel-eluting
tents) for complex coronary lesions (i.e., TCFA or
upture) versus those with underlying stable plaque
orphologies (47% vs. 23%, p  0.01) at a mean of
80 days after stent implantation (3). Neointimal
hickness was also significantly less and inflamma-
ion greater in patients with TCFA/rupture versus
hose with stable plaques. Because sirolimus and
aclitaxel are highly lipophilic, it is likely that these
gents have greater affinity for lipid-rich plaques
i.e., necrotic core) and dwell within the necrotic
ore for longer periods of time because of greater
trut penetration as compared with when struts are
xposed to more fibrotic types of plaque (8).
reater drug concentrations in these areas might
lso heavily influence healing by retarding smooth
uscle cell proliferation as well as endothelial
egrowth. Thrombus burden may also play a role by
ither increasing or decreasing wall uptake of drug,
s shown by Hwang et al. with paclitaxel-eluting
tents (9). These data underscore the concept that
tents require some degree of neointimal hyperpla-
ia to become endothelialized and that although
otal abolition of neointima will result in a larger
umen, it is at the expense of increasing risk for late
tent thrombosis.
Collectively, these data support the contention
hat a significantly increased risk of late thrombotic
omplications should be expected in patients treated
ith DES for complex lesion morphologies. The
act that none of the 55 patients in the study by
ubo et al. (4) developed stent thrombosis or
dverse coronary events is not reassuring, given the
xtremely small sample size and short duration of
he study, as well as coverage by dual-antiplatelet
herapy. Although initial pivotal clinical trials dem-
nstrated that SES were safe in patients with
nstable angina, these patients still have a greater
isk for stent thrombosis than those with stable
ngina (2). Although not specifically examined in
his paper, one might expect that patients present-
ng with myocardial infarction would be at even
reater risk because the underlying lesion morphol-
gies in these patients are often more advanced with
uminal thrombus as compared with patients with
nstable angina. Although randomized long-term
ata from patients receiving DES versus bare-metal
tents for acute myocardial infarction are lacking, Mata from retrospective studies and registries sup-
orts this conclusion. Sianos et al. (10) published a
etrospective study of the effectiveness of DES for
T-segment elevation myocardial infarction dem-
nstrating a 2-year angiographic rate of stent
hrombosis of 3.2%, increasing to 8.2% in those
ith large thrombus burden. More recently, Steg et
l. (11), reporting results from a registry of DES
ersus bare-metal stents for ST-segment elevation
yocardial infarction, found a significantly greater
ate of death between 180 and 730 days after stent
lacement for DES versus bare-metal stents (haz-
rd ratio: 6.7, p  0.002), whereas there was no
ncreased risk in patients treated for nonacute myo-
ardial infarction.
Ultimately, every technology has its limitations,
nd optimal indications for every technology be-
ome apparent only after understanding the limita-
ions. The study by Kubo et al. (4) lends important
nsights into the role of plaque morphology in
ascular healing and suggests significant improve-
ent will have to be made in the existing generation
f DES before they can be used safely in patients
ith complex coronary lesion morphologies.
eprint requests and correspondence: Dr. Renu Virmani,
VPath Institute, Inc., 19 Firstfield Road, Gaithersburg,
Figure 2. Histologic Sections of Stable and Unstable Lesions Wi
Stable lesions demonstrate mild neointimal growth with complete s
strut (*) coverage (left panels). Complex lesions demonstrate a seve
in arterial healing (right panels). Note that struts overlying the necr
area demonstrate a lack of endothelial coverage (arrows), whereas
the opposite side overlying normal medial area are covered by neo
DES  drug-eluting stent; NC  necrotic core; Thr  thrombus.th DES
tent
re delay
otic core
those on
intima.aryland 20878. E-mail: rvirmani@cvpath.org.
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